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There are now a variety of therapies approved for the treatment of metastatic renal cell carcinoma (RCC). These include the
immunotherapeutics, alfa-interferon, and interleukin-2, and agents that target the vascular endothelial growth factor receptor
(VEGFR) via its tyrosine kinase, such as sorafenib, sunitinib, and pazopanib, or the mammalian target of rapamycin (mTOR),
such as temsirolimus and everolimus. Bevacizumab, a monoclonal antibody directed against the ligand, VEGF, has shown activity
against RCC as a single agent in patients who had failed prior cytokine therapy and as ﬁrst line therapy in combination with
interferon. The activity of bevacizumab in patients who had received and failed prior therapy has not been described. We report
our experience in 4 patients with metastatic RCC who had failed prior cytokine, TKI, and mTOR inhibitors who were treated
with bevacizumab as single agent therapy. These heavily pretreated patients sustained very prolonged periods of stable disease
(median of 12 months) with very little toxicity and excellent quality of life. The activity of this agent in patients who had failed
prior therapies directed against the VEGFR and mTOR suggests that therapy targeting the ligand, VEGF, is still a viable approach
in these patients and deserves further study.
1.Introduction
Last year in the United States an estimated 54,390 Americans
were diagnosed with renal cell carcinoma (RCC) and 13,010
died from the disease. The rate of RCC has also been
increasing by 2% per year for the past 65 years with smoking,
obesity, hypertension, cystic kidney disease, and mutation
of the von-Hippel Lindau tumor suppressor gene being
signiﬁcant risk factors [1, 2]. Unfortunately, 30% of patients
present with metastatic disease [3].
Renal cell carcinoma does not response to traditional
chemotherapeutic agents and until the earlier part of this
decade, biologic response modiﬁers such as interleukin-2
(IL-2)andinterferon-α(IFN-α)weretheonlyavailabletreat-
ments[1,4].Morerecently,withanimprovedunderstanding
of the biology of RCC, targeted therapies such as sorafenib,
sunitinib, pazopanib, temsirolimus, and everolimus have
proven to be eﬀective therapies in the metastatic setting
[1]. These agents target the tyrosine kinase of the VEGFR
or the mTOR kinase in the PIK3CA/Akt signaling pathway.
Bevacizumab, a recombinant monoclonal antibody against
the vascular endothelial growth factor-A (VEGF-A) has
also been used as ﬁrst line therapy in Phase III trials in
combination with IFN-α with good results [5, 6] leading to
its approval in metastatic RCC. The activity of bevacizumab
in patients who had already tried and failed TKIs and/or
mTOR inhibitors has not been described. We present a
case series of four patients to illustrate our institutional
experience with single agent bevacizumab as an option for
patients who have failed all other available therapies.
2.CaseReports
2.1. Case One. Patient A was a 73-year-old white male
who was diagnosed with RCC in 2000 and subsequently
underwent a left radical nephrectomy. He went on to have
multiple locoregional recurrences in the nephrectomy bed2 Advances in Urology
and in the lower pole of the right kidney. By January of
2007, he had involvement of the pancreatic tail and the
left adrenal gland as well. He was evaluated at our medical
center in March of 2007. He was restaged at that point
and it was conﬁrmed that he had no disease outside of
the abdomen, so he was oﬀered radical resection of his
disease with curative intent by surgical oncology, but the
patient declined. Therefore, he was started on sunitinib
50mg daily for 4 weeks of a 6 week cycle, and an MRI in
July 2007 showed decrease in the size of the tumor in the
left renal bed and the pancreatic mass and right renal pole
mass remained stable. Imaging after 24 weeks of sunitinib
showed stable disease in known sites. His disease remained
stable until imaging performed in April of 2008, after 36
weeks of treatment, showed clear enlargement of the renal
fossa mass. The patient was then started on temsirolimus
25mg IV weekly for second-line therapy. The patient had
thrombocytopenia, worsening of lipid proﬁle, and elevated
blood glucose levels on temsirolimus that required a 20%
dosereduction.After12weeks,CTscanshowedpneumonitis
consistent with mTOR inhibitor induced pneumonitis, a
possible new lung metastasis, and progression of disease in
the liver and renal fossa. Single agent bevacizumab 10mg/m2
given every 2 weeks was started for third-line therapy and
restaging every 3 months showed continued stable disease.
The patient enjoyed 12 months of stable disease on single
agent bevacizumab. It was stopped despite stable disease
due to development of osteonecrosis of the jaw and patient
request. The patient subsequently progressed rapidly and
expired while oﬀ therapy.
2.2. Case Two. Patient B is a 76-year-old white male who
presented with microscopic hematuria in 1986 on a routine
urinalysis and a diagnosis of left RCC was made by imaging.
He then underwent nephrectomy for a 7 × 6 × 5.5cm
tumor extending though the fascia into the perinephric
fat. He did well until March of 2006 when he had a
routine chest X-ray that showed new lung nodules and a
CT scan was ordered. A large retroperitoneal mass posterior
to the stomach measuring 10 × 9 × 8 cm was also found
along with bilateral lung nodules, with the largest lung
lesion measuring 2cm. Biopsy of the retroperitoneal mass
conﬁrmed RCC. MRI of the brain and bone scan was
negative. He was seen for the ﬁrst time at our institution
in April of 2006. He was determined to be a candidate
for high-dose IL-2 (600,000IU/kg). After 8 weeks, he did
show some response, but was only able to tolerate half of
cycle 2 and he declined further IL-2. He was then started
on sorafenib and had a minor response at all disease sites
until CT scan in January 2007 after 24 weeks showed
progression. He was then switched to sunitinib 50mg daily
for 4 weeks of a 6 weeks cycles, and after 12 weeks on therapy
had a signiﬁcant response which he enjoyed until week
54 when CT scanning showed marked disease progression.
Sunitinib was discontinued and in January of 2008 he was
started on temsirolimus 25mg IV weekly. He required a
20% dose reduction for thrombocytopenia and oral ulcers.
He remained on temsirolimus until April of 2008 when he
developed symptomatic mTOR interstitial pneumonitis, so
temsirolimus was discontinued. His disease continued to
progress oﬀ therapy and in October of 2008, bevacizumab
10mg/m2 given every 2 weeks was started as ﬁfth line
therapy. After 24 weeks of treatment the patient was found
to have a pulmonary embolus. Lovenox was started and
bevacizumab was continued without incident. At the time of
submission, the patient’s disease has remained stable after 72
weeks of bevacizumab. He has continued to work full time as
a maintenance man.
2.3. Case Three. Patient C is a 68-year-old white man who
was diagnosed with metastatic RCC, clear cell type in July
2008 discovered as part of an evaluation for new onset
atrial ﬁbrillation. He had a 7.1 × 9.7cm left renal mass,
enlarged retroperitoneal and mediastinal lymph nodes and
multiple lung nodules. Mediastinal lymph node was positive
for metastatic RCC on biopsy. He underwent debulking
nephrectomy in August 2008 and then had a trial of high-
dose IL-2 (600,000IU/kg) which failed with progressive
disease. He began sunitinib 50mg daily for 4 weeks of a 6
week cycle, and had initially stable disease, but progressed
after 36 weeks. He then began everolimus 10mg daily but
developed symptomatic mTOR-inhibitor-associated pneu-
monitis which resolved with steroids and discontinuation
of everolimus. He then began bevacizumab 10mg/m2 given
every 2 weeks and had an initial minor response then
prolonged stable disease. He remains on therapy at 24 weeks
to date. He continues to be very active, golﬁng regularly and
traveling.
2.4. Case Four. Patient D is a 58-year-old white female
who was diagnosed with a T2, N0, M0 right sided RCC
of clear cell histology in 2001. She underwent radical
nephrectomy and was followed by her urologist who found a
small enlarging left adrenal mass and numerous pulmonary
nodulesconcerningformetastaticdiseasein2005.Metastatic
disease was conﬁrmed via biopsy of a lung lesion and the
patient was started on high-dose IL-2 (600,000IU/kg). After
8 weeks, she had disease progression on CT scan in both
the lung and adrenal gland. She was then treated with
sunitinib 50mg daily for 4 weeks of a 6 week cycle, in the
context of a clinical trial. She required a dose reduction
because of pancytopenia. Imaging after 30 weeks showed
stable pulmonary disease and improvement of the adrenal
lesion and retroperitoneal lymphadenopathy. She remained
on sunitinib with stable disease until September 2007 when
CT scan showed disease progression in aortocaval lymph
nodes. Her treatment was then changed to sorafenib 400mg
BID. She achieved 54 weeks of stable disease until July 2008
when her disease progressed on CT scan. The patient was
then put on temsirolimus 25mg IV weekly until October
of 2008 when, once again, she had disease progression on
CT scan. She was placed on bevacizumab 10mg/m2 every
2 weeks and completed 48 weeks of treatment. She then
progressed on bevacizumab at all sites and began 6th-line
treatment with pazopanib 800mg daily. She continues to be
active and well.Advances in Urology 3
Table 1: Patient characteristics and responses to treatments.
Patient ID Age Gender Prior Treatment Responses to Prior Treatment Bevacizumab best response and duration of response
A7 3 M Sunitinib SD for 54 weeks SD for 48 weeks
T e m s i r o l i m u s P Da f t e r3c y c l e s( 3m o n t h s )
B7 6 M
IL-2 PR after 12 weeks
SD for 72 weeks∗ Sorafenib PR for 24 weeks
Sunitinib PR for 54 weeks
Temsirolimus AE after 12 weeks
C5 6 M
IL-2 PD after 8 weeks
SD for >24 weeks∗ Sunitinib SD for 24 weeks
Temsirolimus AE after 12 weeks
D5 8 F
IL-2 PD after 12 weeks
SD for 48 weeks Sunitinib SD for 84 weeks
Sorafenib SD for 36 weeks
Temsirolimus PD after 12 weeks
SD: Stable disease, PD: Progression of disease, PR: Partial response, AE: Adverse event.
∗Patient still on therapy at the time of publication.
3. Discussion
Until recently, treatment options metastatic RCC were
limited to cytokine therapy with IFN-α and/or high-dose
IL-2 [1]. Sunitinib, pazopanib, and sorafenib are multi-TKIs
thatbetweenthemaﬀectVEGF,c-kit,plateletderivedgrowth
factor-beta (PDGFR-β), FLT3, and BRAF [7, 8]. These drugs
have been approved for metastatic RCC as ﬁrst line or
second line [9–11]. The mTOR inhibitors, temsirolimus and
everolimus, are recommended for poor prognosis patients as
ﬁrst line and for second line after TKI failure, respectively.
The mTOR (mammalian Target of Rapamycin) regulates
many downstream signally paths, including the HIF-1, and
controls metabolism, cell growth and angiogenesis [12, 13].
We report our experience with the recombinant mon-
oclonal antibody to vascular endothelial growth factor A
(VEGF-A),bevacizumab,inheavilypre-treatedpatientswith
RCC. This agent was originally evaluated in a phase II trial
of 116 patients with metastatic RCC who had failed high-
dose IL-2. Patients were randomized to receive low-dose
bevacizumab (3mg/kg), high-dose bevacizumab (10mg/kg),
or placebo. Time to progression (TTP) and response rate
(RR) were evaluated as primary endpoints. In the high-dose
group only, there was a signiﬁcant increase in TTP compared
to placebo (4.8 months versus 2.5 months, P<. 001). The
response rate of high-dose bevacizumab was 10% in this
study, with one patient having a partial response (PR) for
the maximum treatment period of two years. This patient
stoppedtherapyafterthetrialandsubsequentlyhadarelapse
six months later, but enjoyed a second PR after restarting
bevacizumab under a compassionate exemption [14].
The AVOREN trial, a multicenter, randomized, double
blind phase III trial of 641 patients were treated in the
ﬁrst-line setting with bevacizumab (10mg/kg every 2 weeks)
plus IFN-α (9 MIU 3 times weekly) or placebo plus IFN-α.
Patients on the bevacizumab arm experienced a progression
free survival (PFS) of 10.2 month versus 5.4 months in the
placebo arm. Response rate was 30.6% in the bevacizumab
arm versus 12.4% in the placebo arm. There was also a trend
towards improved overall survival [5]. A similar study in the
United States, CALGB 90206, randomized patient to receive
ﬁrst-line bevacizumab (10mg/kg every 2 weeks) plus IFN-α
(9 MIU 3 times weekly) or IFN-α alone. Once again, the
bevacizumab arm produced a superior PFS of 8.5 months
compared to 5.2 months in the IFN-α only arm. Response
rate was 25.5% in the bevacizumab arm versus 13.1% in the
IFN-α alone arm [6]. Patients in both of these studies had
not received any prior systemic treatment for RCC.
The activity of bevacizumab as a single agent in patients
who had already tried and progressed on TKIs and mTOR
inhibitors has not been previously described. Pastorelli and
colleagues recently published a single case report of a 67-
year-old female with metastatic RCC that was treated in the
second line setting with IFN-α (3 MIU three times weekly)
and bevacizumab (10mg/kg) together after achieving a brief
PR on sunitinib. Unfortunately, she had signiﬁcant toxicities
from sunitinib that required dose reductions and prevented
her from switching to another TKI after progression. She
then achieved a PR for eight months on IFN-α and
bevacizumab. Despite the fact that TKIs and bevacizumab
both have antiangiogenic properties, cross-resistance did not
occur in this case and supports our observations [15].
Table 1 lists the characteristics of our 4 responding
patients. To date, we have treated 6 patients in our practice
with late-line bevacizumab after failure of all available prior
therapies. Two patients not presented tolerated treatment
well but did not respond and had clear disease progression
on assessment after 2 to 3 cycles. The other 4 patients
however, exhibited prolonged disease stabilization (median
12 months) with minimal toxicity and excellent quality of
life.Theresponserateinthe6patientstreatedinourpractice
was 67%. In the palliative setting, the side eﬀect proﬁle of
bevacizumab is an important consideration. The most sig-
niﬁcant and consistent adverse events from clinical trials of4 Advances in Urology
bevacizumab were proteinuria, hypertension, fatigue, asthe-
nia, and cytopenias. Bleeding and venous thromboembolism
are always a serious concern when giving anti-VEGF therapy
[14]. In our short case series, Patient B did experience a
pulmonary embolus while on bevacizumab, but this drug
was otherwise well tolerated and he continued therapy while
on anticoagulation. Patient A developed osteonecrosis of
the jaw, an unusual but reported side eﬀect of prolonged
bevacizumab [16]. At the time of this report, three of the
four patients whom we have treated had enjoyed over a
year of stable disease on single agent bevacizumab with an
acceptable side eﬀect proﬁle and good quality of life.
Bevacizumab retained a signiﬁcant prolonged disease
stabilizationeﬀectafterpriorfailureofbothTKIsandmTOR
inhibitors, an observation which has important biological
implications. This suggests that the signaling pathways
within the cytoplasm may be altered to confer resistance
to agents that are active in the cytoplasm such as the TKIs
and mTOR inhibitors, but the pathway is still intact so that
interference with the ligand, VEGF, binding to its receptor
may still suppress tumor growth. Our clinical experience
suggests that bevacizumab should be studied in a larger
group of heavily pre-treated patients in the context of a
clinical trial to better deﬁne its activity. The high-response
rate and tolerability noted in these heavily pre-treated
patients in real clinical practice is certainly encouraging.
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